<DOC>
	<DOCNO>NCT01157481</DOCNO>
	<brief_summary>Patients heart failure preserve ejection fraction equally high risk mortality re-hospitalization reduce ejection fraction . Effective management strategy critically need establish type heart failure . These patient hypertensive ischemic etiology reduce ejection fraction . The investigator hypothesis Ca channel blocker nifedipine improve heart failure clinical composite response endpoint compare conventional treatment patient heart failure hypertension and/or coronary artery disease preserve ejection fraction ( &gt; =50 % ) echocardiography . This study multi-center , prospective , randomize , open-label , blinded-endpoint design .</brief_summary>
	<brief_title>Diastolic Heart Failure Management Nifedipine</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<criteria>1 . 20 year old 2 . Heart failure history hypertension and/or coronary artery disease 3 . LVEF &gt; = 50 % echocardiography 1 . Valvular heart diseases significant regurgitation and/or stenosis 2 . Hypertrophic cardiomyopathy , restrictive cardiomyopathy , arrhythmogenic right ventricular cardiomyopathy , active myocarditis 3 . Constrictive pericarditis 4 . Cardiogenic shock 5 . Planned coronary artery bypass graft percutaneous coronary intervention within 3 month 6 . History acute coronary syndrome stroke within 3 month 7 . Pregnancy breastfeed 8 . Hypersensitivity contraindication nifedipine 9 . Inability obtain informed consent 10 . Any condition suitable participation trial judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diastolic Heart Failure</keyword>
	<keyword>Heart failure preserve ejection fraction</keyword>
	<keyword>nifedipine</keyword>
</DOC>